BiotechTube
OmniSpirant Therapeutics

OmniSpirant Therapeutics

Dublin, Ireland· Est.
omnispirant.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

OmniSpirant Therapeutics is a private, preclinical-stage biotech leveraging its proprietary OmniSome exosome platform to create inhaled regenerative gene therapies for respiratory diseases. The platform combines the natural delivery efficiency of stem cell-derived extracellular vesicles with engineered mucus-penetrating and cell-targeting capabilities. With lead programs in cystic fibrosis (OS001) and lung cancer (OS003), the company is positioned in the high-growth fields of advanced drug delivery and gene therapy. Its partnership with Aerogen for nebulizer delivery and the platform's potential applicability beyond the lungs present significant opportunities for expansion.

Cystic FibrosisOncologyRespiratory Diseases

Technology Platform

OmniSome platform: engineered stem cell-derived exosomes (extracellular vesicles) designed for efficient intracellular delivery of RNA/protein cargo, with mucus-penetrating properties and inherent regenerative effects.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The OmniSome platform's ability to efficiently deliver genetic cargo via inhalation addresses a major unmet need in pulmonary gene therapy for diseases like CF and COPD.
Its applicability beyond the lungs to other organ systems (CNS, liver) through systemic delivery opens vast expansion and partnership potential in broader gene therapy markets.

Risk Factors

As a preclinical company, OmniSpirant faces significant technical risks in scaling exosome manufacturing and proving clinical safety/efficacy.
The regulatory path for novel exosome-based gene therapies is complex and evolving, posing potential delays.
The company is also dependent on securing ongoing funding to advance its programs.

Competitive Landscape

OmniSpirant competes in the rapidly growing field of exosome and extracellular vesicle therapeutics, alongside companies like Codiak BioSciences, Evox Therapeutics, and Aruna Bio. In pulmonary gene delivery, it faces competition from viral vector (e.g., 4D Molecular Therapeutics) and synthetic nanoparticle approaches. Its differentiation lies in combining inhalation delivery, mucus penetration, and inherent regenerative properties in a single platform.

More companies in Cell & Gene Therapy →More companies in Ireland →